- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01478074
ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia
A Single-center Open-label Phase I Study of ALT-801 for ex Vivo Maturation and in Vivo Retargeting of Haploidentical Natural Killer Cells Delivered Following Fludarabine, Cytarabine, and G-CSF in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Hematopoietic stem cell transplantation (SCT) is an effective treatment for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). For patients transplanted in first remission or with low risk MDS, approximately 60% of patients have achieved long-term disease free survival. Patients with relapsed leukemia have a poorer outcome; the long-term disease free survival rate for relapsed AML is 5-10% without hematopoietic stem cell transplantation (HSCT). With HSCT, survival after relapse approaches 40%, but success depends greatly on whether patients are in remission at the time of transplant. Many relapsed patients have refractory chemoresistant disease and never attain remission to be eligible for potentially curative HSCT, or develop significant complicating comorbidities during the prolonged intensive reinduction of their disease. Thus, improved strategies for achieving remission in relapsed patients prior to transplantation are critical to improving the survival of these patients. Relapsed/refractory AML requires remission prior to allogeneic HSCT for optimal survival, but responds poorly to chemotherapy. Human leukocyte antigen (HLA)-haploidentical, NK-enriched peripheral blood cell infusions may augment induction chemotherapy in patients with poor prognosis AML, but there are significant toxicities related to the IL-2 infusions given for optimal NK cell activity. The purpose of this trial is to estimate the toxicity and feasibility of treating relapsed/refractory AML with FLAG chemotherapy followed by haploidentical donor-derived natural killer (NK) cells using ALT-801 for ex vivo and in vivo NK cell activation as an alternative to interleukin-2 (IL-2).
ALT-801 is a genetically engineered fusion protein, that is, a single protein made by combining the DNA of two or more different genes. ALT-801 is a combination of IL-2 (an important protein for stimulating immune cells) and a binding portion that recognizes tumor cells.
The primary objective of this study is to evaluate the safety and feasibility of an infused allogeneic donor NK cell product and ALT-801 following a FLAG preparative regimen to treat relapsed/refractory acute myelogenous leukemia. The primary endpoint for toxicity is the absence of NK cell Product or ALT-801-related grade 2 toxicity, excluding grade 2 fever, rigor/chills, fatigue, vomiting/nausea, pruritus/itching, electrolyte imbalance, hypoalbuminemia or lymphopenia within 21 days of the ALT-801 or NK cell product infusion. The primary endpoint of feasibility is defined as being able to infuse NK-cells at the maximum tolerated cell dose or the highest dose level on day 0 and complete all 8 planned doses of ALT-801, with a safety that does not exceed toxicity limits, in greater than or equal to 7 of 10 subjects.
Study Type
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Recipient Inclusion Criteria:
- Patients with relapsed AML, including those with CNS disease or previous hematopoietic stem cell transplantation, or primary refractory AML (primary AML that has failed remission to at least two cycles of induction therapy)
- For patients of Cohorts 2 to 4, availability of a haploidentical family peripheral blood stem cell donor selected for best possible KIR reactivity
- Patient is between 2 and 59 years of age, inclusive
- Patient must have recovered from the treatment-related toxicities of prior cytotoxic agents received in the 4 weeks prior to beginning treatment on this protocol, with the exception of cytopenias resulting from persistent disease, and alopecia
- Zubrod performance scale (Refer to Appendix C) ≤ 2 or Lansky (Refer to Appendix D) > 60
Adequate renal function defined as:
- For adults serum creatinine < 2 mg/dL
- For children serum creatinine < 2 mg/dL or < 2 times upper limit of normal (ULN) for age (which ever is less) If abnormal creatinine level, 24h creatinine clearance > 60 mL/min/1.73m^2
- Adequate liver function, defined as: Total bilirubin ≤ 2 mg/dL and SGPT (ALT) ≤ 2.5 x ULN for age (unless Gilbert's disease or abnormal liver function due to primary disease)
- Pulmonary symptoms controlled by medication and pulse oximetry> 92% room air
- New York Heart Association classification < III
- Negative serum test to rule out pregnancy within 2 weeks prior to registration in females of childbearing potential (non childbearing potential defined as premenarchal, greater than one year post-menopausal, or surgically sterilized)
- Sexually active males and females of childbearing potential must agree to use a form of contraception considered effective and medically acceptable by the Investigator
- Negative serology for human immunodeficiency virus (HIV)
Recipient Exclusion Criteria:
- Investigational therapies in the 4 weeks prior to beginning treatment on this protocol
- Congestive heart failure < 6 months prior to screening
- Unstable angina pectoris < 6 months prior to screening
- Myocardial infarction < 6 months prior to screening
Donor Inclusion Criteria:
- Related to recipient (sibling, parent, offspring, offspring of a sibling)
- HLA-haploidentical to recipient (need not be re-tested if already performed previously, provided copies of the original results are available)
- Able and willing to undergo apheresis
- Willing to donate blood for baseline chimerism assessment
- Negative serum test to rule out pregnancy within two weeks prior to registration in females of childbearing potential (non childbearing potential defined as premenarchal, greater than one year post-menopausal, or surgically sterilized)
- Donor must meet institutional eligibility criteria for allogeneic blood stem cell donation including infectious disease screening panel (Hepatitis B, Hepatitis C, HIV, CMV, and West Nile Virus) and CBC, differential and platelet studies
- Donor must meet stem cell donor eligibility criteria as set forth in 21 CFR 1271 subpart C
The preferred Donor will be selected as the most alloreactive of the available haploidentical related donors on the basis of predicted NK cell alloreactivity using Recipient and Donor HLA type. If necessary, the best of equally alloreactive donors will be determined by Donor KIR type. NK alloreactivity is defined as o A KIR gene is present on the Donor NK cells for which
- the HLA haplotype (KIR ligand) for the KIR receptor in question is absent in the Recipient, and
- the HLA haplotype (KIR ligand) for the KIR receptor in question is present in the Donor
Donor Exclusion Criteria:
- Active infection (defined as on antimicrobial therapy and/or febrile)
- Pregnant females
- Breast-feeding females
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: FLAG + NK Cells + ALT-801
|
5 mcg/kg daily from day -7 until post-nadir ANC > 1000
2 g/m2 daily from day -6 through -2
30 mg/m2 daily from day -6 through -2
Infused once on day 0. Four cohorts of escalating doses receiving 0, 1, 10, or 20 x 10^6 cells/Kg
0.04 mg/kg IV thrice weekly for 8 doses beginning day +2
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum tolerated dose of NK cells
Time Frame: 18 months
|
Determined by the maximum tolerated dose of NK cells that can be given in combination with ALT-801 with less than 1/3 of patients experience dose-limiting toxicities related to the NK cells or ALT-801.
|
18 months
|
Safety of delivering NK cells and ALT-801 in combination with FLAG
Time Frame: 6 months after study completes accrual
|
Determined by whether the maximum tolerated dose of NK cells can be given in combination with ALT-801 and FLAG chemotherapy without exceeding a rate of 0.28 for >= Grade 3 toxicities (10% above that of FLAG therapy alone) during the treatment period.
|
6 months after study completes accrual
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Activation status of NK cells following activation with ALT-801
Time Frame: 6 months after study completes accrual
|
Activation status of ALT-801-activated NK cells will be determined by measuring NK cell degranulation against standardized targets and comparing with freshly-obtained NK cells.
|
6 months after study completes accrual
|
In vivo persistence and function of haploidentical NK cells activated with ALT-801.
Time Frame: 6 months after study completes accrual
|
Determined by measuring levels of donor NK cells in the blood and their degranulation against standardized targets.
|
6 months after study completes accrual
|
Overall response to this regimen
Time Frame: 6 months after study completes accrual
|
Determined according to AML Response Criteria in NCCN Practice Guidelines for Oncology v.1.2008.
|
6 months after study completes accrual
|
Rate of stem cell transplantation and the time-to-transplantation
Time Frame: 6 months after study completes accrual
|
Determined by reporting how often and at what time patients achieve sufficient remission and health status to receive hematopoietic stem cell transplantation as definitive therapy after receiving this combination of chemotherapy, cellular therapy, and immune therapy.
|
6 months after study completes accrual
|
ALT-801 immunogenicity
Time Frame: 6 months after study completes accrual
|
Determined by measuring levels of anti-ALT-801 antibodies in serum before treatment and at the end of treatment.
|
6 months after study completes accrual
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Hing C Wong, PhD, Altor BioScience
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Fludarabine
- Cytarabine
Other Study ID Numbers
- CA-ALT-801-02-08
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Jacqueline Garcia, MDEli Lilly and CompanyCompletedCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia | Refractory Adult Acute Myeloid LeukemiaUnited States
-
Kronos BioActive, not recruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States, Spain
Clinical Trials on G-CSF
-
Zhongnan HospitalNot yet recruitingGranulocyte Colony-Stimulating FactorChina
-
Sun Yat-sen UniversityRecruitingPD-1 Inhibitor | G-CSFChina
-
Institute of Liver and Biliary Sciences, IndiaCompletedSevere Alcoholic HepatitisIndia
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedDiamond Blackfan AnemiaUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedAplastic AnemiaUnited States
-
Axaron Bioscience AGCompleted
-
Centre for Endocrinology and Reproductive Medicine...UnknownInfertility | Embryo Development | IVFItaly
-
National Heart, Lung, and Blood Institute (NHLBI)New York University and New York Genome CenterRecruitingGraft-Versus-Host Disease | Graft-versus-leukemia | Donor ApheresisUnited States
-
GPCR Therapeutics, Inc.CompletedMultiple Myeloma | Hodgkin Disease | Non-Hodgkin LymphomaUnited States